Five ‘Big Idea’ Biotech Trends To Watch In 2017

Five ‘Big Idea’ Biotech Trends To Watch In 2017

(Photo credit should read REMY GABALDA/AFP/Getty Images)

Different types of stories cross my radar as a biotech journalist every day.

There are partnerships between established drugmakers that need new products and the little aspiring companies that need cash to develop their thing. Stories about clinical trial results that move markets. Regulatory actions that make or break companies and investors.

But for me, there’s something especially fun about talking with scientific entrepreneurs who raised their first big wad of investment cash. They’re latching onto some kernel of insight from a discovery. Or maybe they have a vision for stitching together a set of technologies. Either way, they are venturing into a great unknown to see if they can make a big step ahead in medicine. They often have insights that put them years ahead of the lumbering drug giants.

 

Source: https://www.forbes.com/sites/luketimmerman/2016/12/27/five-big-idea-biotech-trends-to-watch-in-2017/2/#6368d858f501

Related Post

신약 R&BD ‘바이오콘’ 주목…11개 파이프라인...
views 2054
신약 R&BD '바이오콘' 주목...11개 파이프라인 진행 제약바이오기업과 고효율 신약개발 플랫폼 구축-신약 타깃 개발 추진 이권구 기자 | kwon9@yakup.com    기사입력 2016-06-20 06:41     최종수정 2016-06-20 ...
Challenges and Opportunities in Translation of Aca...
views 590
(메디포뉴스=홍숙기자) 등록 2018-06-08 09:58:52 Challenges and Opportunities in Translation of Academic가 8일 오전 9시부터 삼성서울병원에서 진행되고 있다. 이날 행사는 김성훈 의약바이오컨버...
A paper on a new ARS receptor was published in the...
views 459
Dr. Hyuck Sang Kwon's article was published in the Journal of Cell Science for discovering  a new AIMP1 receptor.   The title of the article...
백신 개발·DNA 해독… 전염병 막을 ‘국제연합군’ 뭉쳤다...
views 545
백신 개발·DNA 해독… 전염병 막을 '국제연합군' 뭉쳤다 박건형 기자 황승식 서울대 보건대학원 교수 입력 : 2017.06.03 03:02 판데믹에 맞서는 인류 WHO·美·유럽 중심으로 에볼라 백신 개발 성공 빌 게이...

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

©2010-2018 Medicinal Bioconvergence Research Center. All rights reserved.

Log in with your credentials

Forgot your details?

Skip to toolbar